Cizman M
Department of Infectious Diseases, University Medical Center Ljubljana, Slovenia.
Euro Surveill. 2008 Nov 13;13(46):19038.
During 1991-1999 a significant increase of consumption of macrolides and fluoroquinolones was observed in Slovenia,and this was associated with significant increase of resistance of Streptococcus pneumoniae and Streptococcus pyogenes to macrolides and Escherichia coli to fluoroquinolones, respectively.Between 1999 and 2007 the prevalence of S. pneumoniae resistant to erythromycin increased from 3.7% to 16.8% even though the use of macrolides in the same period decreased from 3.81 to 2.43 defined daily doses (DDD) per 1,000 inhabitants and per day. The co-resistance and the spread of resistant clones were the reason for constant increase in macrolide resistance. Slovenia is one of the few European countries with decreasing prevalence of methicillin resistant Staphylococcus aureus (MRSA) in hospital care during the last years. As a result of control measures introduced in 1999,the MRSA prevalence rates decreased from 21.4% in 2000 to 8.3% in 2007.
1991年至1999年期间,斯洛文尼亚观察到大环内酯类药物和氟喹诺酮类药物的消费量显著增加,这分别与肺炎链球菌和化脓性链球菌对大环内酯类药物的耐药性显著增加以及大肠杆菌对氟喹诺酮类药物的耐药性显著增加有关。1999年至2007年期间,对红霉素耐药的肺炎链球菌患病率从3.7%升至16.8%,尽管同期大环内酯类药物的使用量从每1000居民每天3.81限定日剂量(DDD)降至2.43 DDD。共同耐药性和耐药克隆的传播是大环内酯类药物耐药性持续增加的原因。斯洛文尼亚是过去几年中少数几个医院护理中耐甲氧西林金黄色葡萄球菌(MRSA)患病率下降的欧洲国家之一。由于1999年采取的控制措施,MRSA患病率从2000年的21.4%降至2007年的8.3%。